Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma
Dark genome-focused biotech Rome Therapeutics has completed an oversubscribed $72 million Series B extension supported by new Big Pharma backers, with an eye to advancing its lead anti-inflammatory program into clinical trials.
The Boston-based company raised $77 million in its original Series B round in September 2021 and has now completed the extension phase supported by investors, including the venture arms of Sanofi, Bristol Myers Squibb and Johnson & Johnson, bringing the total to $149 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.